440 related articles for article (PubMed ID: 25929918)
21. Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib.
Wicherts DA; van Coevorden F; Klomp HM; van Huizum MA; Kerst JM; Haas RL; van Boven HH; van der Hage JA
World J Surg Oncol; 2013 Mar; 11():59. PubMed ID: 23496933
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of metastatic fibrosarcomatous dermatofibrosarcoma protuberans with imatinib mesylate.
Kambayashi Y; Kasahara Y; Ohuchi K; Amagai R; Hashimoto A; Asano Y; Fujimura T
Dermatol Ther; 2022 Oct; 35(10):e15736. PubMed ID: 35898161
[TBL] [Abstract][Full Text] [Related]
23. Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp.
Kasper B; Lossignol D; Gil T; Flamen P; De Saint Aubain N; Awada A
Anticancer Drugs; 2006 Nov; 17(10):1223-5. PubMed ID: 17075323
[TBL] [Abstract][Full Text] [Related]
24. Genetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencing.
Hong JY; Liu X; Mao M; Li M; Choi DI; Kang SW; Lee J; La Choi Y
PLoS One; 2013; 8(7):e69752. PubMed ID: 23922791
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of Imatinib Mesylate Treatment in a Patient with Dermatofibrosarcoma Protuberans with Pulmonary and Pancreatic Metastases.
Tatai T; Gomi D; Fukushima T; Kobayashi T; Sekiguchi N; Sakamoto A; Sasaki S; Koizumi T; Sano K
Intern Med; 2016; 55(17):2507-11. PubMed ID: 27580559
[TBL] [Abstract][Full Text] [Related]
26. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans.
Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A
Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058
[TBL] [Abstract][Full Text] [Related]
27. Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease.
McArthur GA
J Natl Compr Canc Netw; 2007 May; 5(5):557-62. PubMed ID: 17509258
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection.
Rutkowski P; Dębiec-Rychter M; Nowecki Z; Michej W; Symonides M; Ptaszynski K; Ruka W
J Eur Acad Dermatol Venereol; 2011 Mar; 25(3):264-70. PubMed ID: 20569296
[TBL] [Abstract][Full Text] [Related]
29. Dermatofibrosarcoma protuberans: is mohs surgery truly superior? And the success of tyrosine kinase inhibitors.
Kallini JR; Khachemoune A
J Drugs Dermatol; 2014 Dec; 13(12):1474-7. PubMed ID: 25607791
[TBL] [Abstract][Full Text] [Related]
30. Dermatofibrosarcoma protuberans: clinical series, national Danish incidence data and suggested guidelines.
Akram J; Wooler G; Lock-Andersen J
J Plast Surg Hand Surg; 2014 Feb; 48(1):67-73. PubMed ID: 23837507
[TBL] [Abstract][Full Text] [Related]
31. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP).
Gooskens SL; Oranje AP; van Adrichem LN; de Waard-van der Spek FB; den Hollander JC; van de Ven CP; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2010 Aug; 55(2):369-73. PubMed ID: 20582941
[TBL] [Abstract][Full Text] [Related]
32. Response of malignant scalp dermatofibrosarcoma to presurgical targeted growth factor inhibition.
Mattox AK; Mehta AI; Grossi PM; Cummings TJ; Adamson DC
J Neurosurg; 2010 May; 112(5):965-77. PubMed ID: 19681684
[TBL] [Abstract][Full Text] [Related]
33. Dermatofibrosarcoma protuberans with fibrosarcomatous transformation: a case report.
Hrudka J; Charvát M; Grossmann P; Kinkor Z
Cesk Patol; 2020; 56(2):89-93. PubMed ID: 32493025
[TBL] [Abstract][Full Text] [Related]
34. Current treatment options for dermatofibrosarcoma protuberans.
Rutkowski P; Debiec-Rychter M
Expert Rev Anticancer Ther; 2015; 15(8):901-9. PubMed ID: 26027711
[TBL] [Abstract][Full Text] [Related]
35. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
36. Hyalinized collagen in a dermatofibrosarcoma protuberans after treatment with imatinib mesylate.
Thomison J; McCarter M; McClain D; Golitz LE; Goldenberg G
J Cutan Pathol; 2008 Nov; 35(11):1003-6. PubMed ID: 18544062
[TBL] [Abstract][Full Text] [Related]
37. A Multicenter Phase II Study of Pazopanib in Patients with Unresectable Dermatofibrosarcoma Protuberans.
Delyon J; Porcher R; Battistella M; Meyer N; Adamski H; Bertucci F; Guillot B; Jouary T; Leccia MT; Dalac S; Mortier L; Ghrieb Z; Da Meda L; Vicaut E; Pedeutour F; Mourah S; Lebbe C
J Invest Dermatol; 2021 Apr; 141(4):761-769.e2. PubMed ID: 32956651
[TBL] [Abstract][Full Text] [Related]
38. Dermatofibrosarcoma protuberans: clinical, pathological, and genetic (COL1A1-PDGFB ) study with therapeutic implications.
Llombart B; Sanmartín O; López-Guerrero JA; Monteagudo C; Serra C; Requena C; Poveda A; Vistós JL; Almenar S; Llombart-Bosch A; Guillén C
Histopathology; 2009 Jun; 54(7):860-72. PubMed ID: 19635106
[TBL] [Abstract][Full Text] [Related]
39. Dermatofibrosarcoma protuberans: a comprehensive review and update on diagnosis and management.
Llombart B; Serra-Guillén C; Monteagudo C; López Guerrero JA; Sanmartín O
Semin Diagn Pathol; 2013 Feb; 30(1):13-28. PubMed ID: 23327727
[TBL] [Abstract][Full Text] [Related]
40. Fine-needle aspiration of dermatofibrosarcoma protuberans metastasizing to hemithorax with superior vena cava compression: Case report and literature review.
Banach BS; Antic T; Bridge JA; Cipriani NA; Frye L; Krausz TN; Biernacka A
Diagn Cytopathol; 2019 Aug; 47(8):797-802. PubMed ID: 30919592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
